XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Stock award plan - (Tables)
3 Months Ended
Mar. 31, 2023
Share-based Payment Arrangement [Abstract]  
Summary of stock option activity

    

    

    

Weighted-

    

  

Weighted-

average

Aggregate

average

remaining

intrinsic

Number of

exercise

contractual

value(in 

options

price

term

thousands)

 

Outstanding at December 31, 2022

 

11,502,417

$

43.33

 

  

 

  

Granted

 

863,410

$

39.93

 

  

 

  

Exercised

 

(211,561)

$

28.61

 

  

 

  

Forfeited/Cancelled

 

(53,716)

$

52.25

 

  

 

  

Outstanding at March 31, 2023

 

12,100,550

$

43.30

 

6.38

years

$

102,959

Vested or Expected to vest at March 31, 2023

 

3,387,505

$

47.15

 

8.44

years

$

19,149

Exercisable at March 31, 2023

 

8,348,132

$

41.68

 

5.44

years

$

81,335

Schedule of assumptions used to estimate fair values of grants made on the date of grant

    

Three months ended

    

March 31, 2023

Risk-free interest rate

 

3.54% - 3.88%

Expected volatility

 

54%

Expected term

 

5.5 years

Summary of information on the Company's restricted stock

Restricted Stock Awards and Units

Weighted

Average

Grant

Number of

Date

    

Shares

    

Fair Value

Unvested at December 31, 2022

2,516,336

$

45.67

Granted

 

1,861,235

39.55

Vested

 

(701,066)

46.82

Forfeited

 

(26,763)

43.62

Unvested at March 31, 2023

 

3,649,742

$

42.34

Schedule of share-based compensation expense recorded in the statement of operations

Three Months Ended March 31, 

    

2023

    

2022

Research and development

$

15,314

$

13,034

Selling, general and administrative

 

13,501

 

13,555

Total

$

28,815

$

26,589